cystatin like 1Genealiases: CTES1 · RCET11 · dJ322G13.4
Q-omics provides the consensus-scored CSTL1 profile across patient tissues and cancer cell-line models. CSTL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CSTL1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CSTL1 protein abundance shows 13,516 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KICH, COAD, and HNSC as cancer lineages where CSTL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSTL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSTL1 survival associations across molecular data types. CSTL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSTL1 RNA expression–survival associations across cancer types. High CSTL1 expression shows unfavorable associations in KICH, BLCA, ACC and THCA, but favorable associations in BRCA and MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CSTL1 RNA expression.
This table summarizes CSTL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CSTL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSTL1 shows higher tumor expression in COAD, HNSC, LUSC, BLCA, LUAD and BRCA. The COAD box plot shows higher CSTL1 RNA expression in tumor versus normal tissue (log2 FC = +0.475, t-test p < 0.001).
This table shows molecular features associated with CSTL1 in patient tissues and cancer cell lines. In patient samples, CSTL1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, CSTL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and STOMACH.
